In many patients, clopidogrel causes fewer upper gastrointestinal adverse events than aspirin. However, there are currently no data on the use of this drug in high-risk patients.
In this study, a team of physicians from China and Spain evaluated the safety of clopidogrel in patients with peptic ulcer disease.
The research team assessed 70 patients received clopidogrel for either non-aspirin-related peptic ulcer disease or aspirin-related gastrointestinal complications.
|12% of patients developed gastrointestinal bleeding.|
|Alimentary Pharmacology and Therapeutics|
The primary end-point was occurrence of ulcer complications.
The physicians determined that, following a median follow-up of 1 year, 12% of patients developed gastrointestinal bleeding, while 1% had a perforated peptic ulcer.
They found that clopidogrel-associated gastrointestinal bleeding occurred more commonly in patients with a history of gastrointestinal bleeding than in those without.
Dr Ng's team concluded, "Clopidogrel is associated with a high incidence of upper gastrointestinal bleeding in high-risk patients".
"A previous history of gastrointestinal bleeding appears to be a predictor of adverse gastrointestinal events".